Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 SOURCE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING INCIDENCE OF HEREDITARY CANCER
6.1.2 INCREASE IN THE GERIATRIC POPULATION
6.1.3 RISING HEALTHCARE SPENDING
6.1.4 INCREASE IN AWARENESS ABOUT CANCER TESTING
6.2 RESTRAINTS
6.2.1 HIGH COST OF HEREDITARY CANCER TESTING
6.2.2 LACK OF SKILLED PROFESSIONALS
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS
6.3.2 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS
6.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS
6.3.4 TECHNOLOGICAL DEVELOPMENTS IN HEREDITARY CANCER TESTING PROCEDURES
6.4 CHALLENGES
6.4.1 ETHICAL CHALLENGES FACED DURING HEREDITARY CANCER TESTING
6.4.2 RISING COMPETITION AMONG MARKET PLAYERS
7 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE
7.1 OVERVIEW
7.2 MULTI PANEL TEST
7.3 SINGLE-SITE GENETIC TEST
8 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE
8.1 OVERVIEW
8.2 BIOPSY
8.2.1 NEEDLE BIOPSIES
8.2.2 ENDOSCOPIC BIOPSIES
8.2.3 LAPAROSCOPIC, THORACOSCOPIC, AND MEDIASTINOSCOPIC BIOPSY
8.2.4 LAPAROTOMY AND THORACOTOMY
8.2.5 OTHERS
8.3 IMAGING
8.3.1 MAGNETIC RESONANCE IMAGING (MRI)
8.3.2 COMPUTED TOMOGRAPHY (CT) SCAN
8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN
8.3.4 NUCLEAR SCAN
8.3.5 ULTRASOUND
8.3.6 X-RAYS
8.4 LAB TESTS
8.4.1 BLOOD
8.4.2 URINE
8.4.3 OTHERS
9 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 POLYMERASE CHAIN REACTION (PCR)
9.3 SEQUENCING
9.4 MICRO ARRAY
10 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE
10.1 OVERVIEW
10.2 HEREDITARY BREAST & OVARIAN CANCER SYNDROME
10.3 COWDEN SYNDROME
10.4 LYNCH SYNDROME
10.5 HEREDITARY LEUKEMIA AND HEMATOLOGIC MALIGNANCIES SYNDROME
10.6 FAMILIAL ADENOMATOUS POLYPOSIS (FAP)
10.7 LI-FRAUMENI SYNDROME
10.8 VON HIPPEL-LINDAU DISEASE
10.9 MULTIPLE ENDOCRINE NEOPLASIAS (MEN) SYNDROME
11 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 CLINICS
11.4 DIAGNOSTIC CENTERS
11.5 RADIOLOGY CENTERS
11.6 LABORATORIES
11.7 OTHERS
12 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
13 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY REGION
13.1 MIDDLE EAST AND AFRICA
13.1.1 SOUTH AFRICA
13.1.2 SAUDI ARABIA
13.1.3 U.A.E.
13.1.4 EGYPT
13.1.5 ISRAEL
13.1.6 REST OF THE MIDDLE EAST AND AFRICA
14 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 ABBOTT
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 ILLUMINA, INC. (2021)
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 PERKINELMER INC. (2021)
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 LIFELABS GENETICS
16.4.1 COMPANY SNAPSHOT
16.4.2 COMPANY SHARE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENTS
16.5 EUROFINS SCIENTIFIC (2021)
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 AMBRY GENETICS
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENTS
16.7 BIOCARTIS
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENTS
16.8 BIO-HELIX
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENTS
16.9 BIOREFERENCE (A SUBSIDIARY OF OPKO HEALTH, INC.) (2021)
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENT
16.1 CENTOGENE N.V. (2021)
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
16.11 CEPHEID
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENT
16.12 FULGENT GENETICS
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENT
16.13 INVITAE CORPORATION
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENT
16.14 NATERA, INC. (2021)
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENTS
16.15 4BASECARE.
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
List of Table
TABLE 1 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 2 MIDDLE EAST & AFRICA MULTI PANEL TEST IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA SINGLE-SITE GENETIC TEST IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA IMAGING IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA IMAGING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA POLYMERASE CHAIN REACTION (PCR) IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA SEQUENCING IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA MICROARRAY IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA HEREDITARY BREAST & OVARIAN CANCER SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA COWDEN SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA LYNCH SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA HEREDITARY LEUKEMIA AND HEMATOLOGIC MALIGNANCIES SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS (FAP) IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA LI-FRAUMENI SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA VON HIPPEL-LINDAU DISEASE IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA MULTIPLE ENDOCRINE NEOPLASIAS (MEN) SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA HOSPITALS CENTERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA CLINICS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA DIAGNOSTIC CENTERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA RADIOLOGY CENTERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA LABORATORIES IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA OTHERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA DIRECT TENDER IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA RETAIL SALES IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA HEREDITARY CANCER TESTING MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 44 SOUTH AFRICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 45 SOUTH AFRICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 46 SOUTH AFRICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 47 SOUTH AFRICA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 48 SOUTH AFRICA BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 49 SOUTH AFRICA IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 50 SOUTH AFRICA LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 51 SOUTH AFRICA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 52 SOUTH AFRICA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 53 SOUTH AFRICA HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 54 SOUTH AFRICA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 55 SAUDI ARABIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 56 SAUDI ARABIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 57 SAUDI ARABIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 58 SAUDI ARABIA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 59 SAUDI ARABIA BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 60 SAUDI ARABIA IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 61 SAUDI ARABIA LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 62 SAUDI ARABIA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 63 SAUDI ARABIA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 64 SAUDI ARABIA HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 65 SAUDI ARABIA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 66 U.A.E. HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 67 U.A.E. HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 68 U.A.E. HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 69 U.A.E. HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 70 U.A.E. BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 71 U.A.E. IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 72 U.A.E. LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 73 U.A.E. HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 74 U.A.E. HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 75 U.A.E. HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 76 U.A.E. HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 77 EGYPT HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 78 EGYPT HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 79 EGYPT HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 80 EGYPT HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 81 EGYPT BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 82 EGYPT IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 83 EGYPT LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 84 EGYPT HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 85 EGYPT HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 86 EGYPT HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 87 EGYPT HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 88 ISRAEL HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 89 ISRAEL HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 90 ISRAEL HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 91 ISRAEL HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 92 ISRAEL BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 93 ISRAEL IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 94 ISRAEL LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 95 ISRAEL HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 96 ISRAEL HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 97 ISRAEL HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 98 ISRAEL HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 99 REST OF MIDDLE EAST AND AFRICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: SEGMENTATION
FIGURE 11 EXPANDING REPRODUCTIVE GENETIC HEALTH SPACE IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET IN THE FORECAST PERIOD
FIGURE 12 MULTI PANEL TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET
FIGURE 14 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY TEST TYPE, 2021
FIGURE 15 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY TEST TYPE, 2022-2029 (USD MILLION)
FIGURE 16 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY TEST TYPE, CAGR (2022-2029)
FIGURE 17 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 18 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY DIAGNOSIS TYPE, 2021
FIGURE 19 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY DIAGNOSIS TYPE, 2022-2029 (USD MILLION)
FIGURE 20 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY DIAGNOSIS TYPE, CAGR (2022-2029)
FIGURE 21 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY DIAGNOSIS TYPE, LIFELINE CURVE
FIGURE 22 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET : BY TECHNOLOGY, 2021
FIGURE 23 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET : BY TECHNOLOGY, 2020-2029 (USD MILLION)
FIGURE 24 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET : BY TECHNOLOGY, CAGR (2022-2029)
FIGURE 25 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET : BY TECHNOLOGY, LIFELINE CURVE
FIGURE 26 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY DISEASE TYPE, 2021
FIGURE 27 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY DISEASE TYPE, 2022-2029 (USD MILLION)
FIGURE 28 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY DISEASE TYPE, CAGR (2022-2029)
FIGURE 29 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 30 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET : BY END USER, 2021
FIGURE 31 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET : BY END USER, 2020-2029 (USD MILLION)
FIGURE 32 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET : BY END USER, CAGR (2022-2029)
FIGURE 33 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET : BY END USER, LIFELINE CURVE
FIGURE 34 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET : BY DISTRIBUTION CHANNEL, 2021
FIGURE 35 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET : BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 36 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET : BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 37 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: SNAPSHOT (2021)
FIGURE 39 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY COUNTRY (2021)
FIGURE 40 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY COUNTRY (2022 & 2029)
FIGURE 41 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY COUNTRY (2021 & 2029)
FIGURE 42 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY TEST TYPE (2022-2029)
FIGURE 43 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: COMPANY SHARE 2021 (%)
